Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Current Leases (2018 - 2025)

Cytosorbents (CTSO) has disclosed Current Leases for 8 consecutive years, with $518000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases rose 19.91% year-over-year to $518000.0, compared with a TTM value of $518000.0 through Sep 2025, up 19.91%, and an annual FY2024 reading of $453000.0, up 21.24% over the prior year.
  • Current Leases was $518000.0 for Q3 2025 at Cytosorbents, up from $495000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $570566.0 in Q4 2021 and bottomed at $108939.0 in Q4 2022.
  • Average Current Leases over 5 years is $359651.2, with a median of $412067.0 recorded in 2024.
  • The sharpest move saw Current Leases plummeted 80.91% in 2022, then soared 268.59% in 2024.
  • Year by year, Current Leases stood at $570566.0 in 2021, then tumbled by 80.91% to $108939.0 in 2022, then skyrocketed by 242.98% to $373636.0 in 2023, then rose by 21.24% to $453000.0 in 2024, then grew by 14.35% to $518000.0 in 2025.
  • Business Quant data shows Current Leases for CTSO at $518000.0 in Q3 2025, $495000.0 in Q2 2025, and $473889.0 in Q1 2025.